Ampersand Capital Partners acquires Vibalogics GmbH

Vibalogics will expand capabilities to meet rapidly growing demand for development and manufacturing of complex viral products

Vibalogics GmbH is being acquired by private equity firm, Ampersand Capital Partners. Ampersand’s growth investment will be used to expand Vibalogics’ capabilities to meet rapidly growing industry demand for the development and manufacturing of complex viral products.

The CDMO focused on complex live biological products offers process development, manufacturing and fill & finish of products for biopharmaceutical companies involved in the development of oncolytic viral therapies, gene therapies, and vaccines.

With a specific focus on viruses, live bacteria, and aseptic processing, the company’s 50 employees work in full compliance with international GMP standards in a BSL-2 classified, 2,500 sqm facility in Cuxhaven, Germany.

Stefan Beyer, CEO of Vibalogics, said: “With the benefit of Ampersand as our partner, Vibalogics will now strengthen and expand its position in the US and European markets while further investing in additional process development and GMP manufacturing capabilities. The partnership solidifies Vibalogics’ existing presence in the biologics manufacturing space and will allow the company to continue to exceed our customers’ expectations by facilitating the development of innovative therapeutic approaches that significantly improve the treatment of patients suffering from cancer and genetic disorders.”

David Anderson, General Partner at Ampersand, said, “Vibalogics is a leading company in its field. Given the exciting developments within the complex virus market, this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company. We are looking forward to working with the team at Vibalogics to accelerate and continue its success in delivering cutting edge therapies to patients in need.”

In May, the German CDMO added a new manufacturing line of 50 L and 200 L single-use bioreactors and a Siemens process control system at the Cuxhaven site. The expansion represents an investment of €1.2 million ($1.35 million), Vibalogics told Bioprocess Insider, and also includes an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with the increased volumes involved in this scale of operation.

Companies